 |
Indication & Dosage |
| |
| |
| Intravenous |
| TREATMENT OF ACUTE MYOCARDIAL INFARCTION |
| Adult:
1.5 million units as a single dose infused over 1 hr immediately after the onset of symptoms. |
| |
| Intravenous |
| TREATMENT OF PULMONARY THROMBOEMBOLISM AND OTHER ARTERIOVENOUS OCCLUSIONS |
| Adult:
Loading dose: 250,000 units infused over 30 min. Maintenance: 100,000 units/hr for 24-72 hr depending on the condition to be treated. For cerebral retinal thrombosis, 12 hr may be sufficient. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values. |
| |
| Intravenous |
| PULMONARY THROMBOEMBOLISM AND OTHER ARTERIOVENOUS OCCLUSIONS |
| Child:
Loading dose: 2500-4000 units/kg over 30 min, followed by infusion of 500-1000 units/kg/hr, continued until reperfusion occurs, up to 3 days. Initial dose may be estimated by streptokinase resistance test. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values. |
|
| |
|
| Precautions |
Mitral stenosis associated with AF. Streptokinase treatment within last 12 mth, use after prolonged or traumatic CPR; diabetic retinopathy. Elderly. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Fever, chills, back pain, abdominal pain, nausea, vomiting, arrhythmia, bruising, rash, pruritus, acute renal failure due to embolism and haemorrhage. Cerebral, peripheral and pulmonary embolism. Allergic reactions, liver enzyme abnormalities, hypotension. |
| |
|
| Adverse Drug Reactions |
Haemorrhage; anaphylactic shock. |
| |
|
| Interactions |
Antagonistic effects with antifibrinolytic agents e.g. aminocaproic acid. |
| |
|
|
|
